Application of a brown gray mushroom extract in preparing drugs for preventing and treating inflammatory bowel disease

Through the preparation and application of brown grey chrysanthemum extract, the problem of high side effects and high cost of drug treatment of ulcerative colitis in the prior art has been solved, effectively preventing and treating inflammatory bowel disease, and providing a safe and efficient drug Solution.

CN117137956BActive Publication Date: 2024-12-03SOUTH CENTRAL UNIVERSITY FOR NATIONALITIES
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211669811.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-12-25
Publication Date
2024-12-03
Estimated Expiration
2042-12-25

AI Technical Summary

Technical Problem

There is a lack of effective drugs for treating ulcerative colitis in the prior art. The existing drugs have high side effects, high cost and poor compliance, and there are no special measures for the treatment of inflammatory bowel disease.

Method used

The extract of brown grey mushroom was used as the active ingredient, and the extract of brown grey mushroom was prepared by pretreatment, ethanol extraction and ethyl acetate extraction. It was used to prepare drugs to prevent and treat inflammatory bowel disease, and to verify its prevention and treatment effect through mouse experiments. .

Benefits of technology

The extract of brown grey mushrooms significantly reduced the disease activity index in mice, relieved the symptoms of colon shortening, diarrhea and bleeding stools, alleviated tissue inflammatory cells infiltration, protected the colon mucosa, and exerted anti-inflammatory effects by inhibiting NO production, providing a Safe and efficient anti-inflammatory bowel disease medication options.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004015854190000071
    Figure BDA0004015854190000071
  • Figure HDA0004015854200000011
    Figure HDA0004015854200000011
  • Figure HDA0004015854200000012
    Figure HDA0004015854200000012
Patent Text Reader

Abstract

The invention relates to the technical field of pharmaceutical use of plant extracts, and discloses an application of a brown-gray mushroom extract in the preparation of a drug for preventing and treating inflammatory bowel disease, the steps comprising: washing, drying and crushing the brown-gray mushroom, adding ethanol, extracting and recovering by vacuum distillation, obtaining an aqueous solution of the brown-gray mushroom extract, adding ethyl acetate for extraction, and vacuum distilling to remove the solvent and recovering the brown-gray mushroom extract. The process is economical, low-cost, simple and easy to implement, has no environmental pressure, and is easy to realize industrialization and large-scale production; the brown-gray mushroom, which is cheap and easily available, is extracted, and the obtained active extract has significant anti-inflammatory bowel disease activity, and can be used to prepare drugs, auxiliary drugs, etc. for preventing or treating colitis. The invention makes full resource utilization of the brown-gray mushroom and reduces the waste of resources.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the application of plant extracts, in particular to the application of a Tricholoma australis extract in preparing a medicine for preventing and treating inflammatory bowel disease. Background Art

[0002] Inflammatory bowel disease (IBD) is a nonspecific intestinal disease characterized by chronic inflammation and ulcer formation. There is no specific cure for it. It is a stubborn disease of the digestive system. Clinically, abdominal pain, diarrhea, weight loss, bloody and mucous stools, and tenesmus are the main symptoms. The lesions of this disease are mainly in the mucosa and submucosa of the colon, with ulcers and edema as the main symptoms. It often involves the rectum, distal colon, and even the entire colon. Its onset is the result of the combined effects of multiple factors, mechanisms, and links. The course of the disease is long, and the disease is prone to recurrence and protracted, and it can cause serious complications and the possibility of cancer. It has been listed as one of the difficult to cure diseases in modern times by the World Health Organization. In recent years, due to the continuous improvement of living standards, the dietary structure has undergone tremendous changes. The incidence of ulcerative colitis (UC) has increased year by year worldwide, and the incidence in my country has also tended to increase. The pathogenesis of UC is still unclear, mainly involving genetic susceptibility, epithelial barrier defects, immune response disorders, and environmental factors. The disease is a chronic inflammation of the intestinal mucosa. The lesions are mostly in the rectum and can even spread to the proximal colon. The main clinical manifestations are bloody diarrhea, abdominal pain, blood in the stool, weight loss, etc. UC has a long course and is prone to recurrence. It may even develop into colon cancer. It is recognized by the WHO as a modern intractable disease. Its pathogenesis is very complex and is still unclear.

[0003] Conventional clinical drug treatments include aminosalicylic acid preparations, steroids, immunosuppressants, etc. Some refractory ulcerative colitis or colon cancer require colectomy, which greatly affects the patient's quality of life. At present, the commonly used drugs for patients with mild and moderate UC are aminosalicylic acid preparations including mesalazine and sulfasalazine, but these preparations have large dosages and obvious side effects, and patient compliance is poor. Patients with moderate and severe UC often use the immunosuppressant infliximab, but it is extremely expensive and often accompanied by withdrawal reactions. Therefore, there is an urgent need to develop more safe and effective therapeutic drugs. Therefore, it is crucial to find a safe and effective drug for the treatment of UC from natural products.

[0004] Tricholomatreum is a wild mushroom, known as small gray mushroom or gray mushroom in many places in North China. It is an edible wild mushroom that grows in groups or scattered on the ground in pine forests or mixed forests in summer and autumn. It grows in large quantities in pine forests in Northeast China and North China. According to records, Epigyneae belongs to the subphylum Basidiomycetes, class Hymenomycetes, subclass Asteraceae, order Agaricales, family Trichodina, genus Trichodina, and contains rich nutrients and multiple trace elements. However, there are no literature reports on the research of its extracts in preventing and treating gastrointestinal inflammatory diseases such as inflammatory bowel disease at home and abroad. Summary of the invention

[0005] In view of the shortcomings of the prior art, the present invention aims to provide a method for preparing a Tricholoma australis extract and the use of the Tricholoma australis extract in preventing and treating inflammatory bowel disease. The inflammatory bowel disease prevention and treatment drug prepared in the present invention uses the Tricholoma australis extract as an active ingredient, and may also be added with one or more excipients acceptable in pharmaceutical preparations, or may be compounded with other active ingredients to exert a synergistic effect of an anti-inflammatory bowel disease drug.

[0006] The present invention is devoted to the experimental research on the preparation of Tricholoma australis extract for preventing and treating inflammatory bowel disease. Mouse experiments have confirmed that the Tricholoma australis extract has a significant preventive and therapeutic effect on inflammatory bowel diseases such as colitis.

[0007] In order to achieve the above technical purpose, the present invention adopts the following technical solutions:

[0008] (1) Pretreatment: Clean the brown gray Agaricus, remove dust and granular impurities on the surface, dry at low temperature (no more than 60° C., preferably 50-60° C.), and then crush to obtain brown gray Agaricus powder as an extraction raw material;

[0009] (2) Extracting the crude product of Agaricus truncatus: adding ethanol to a certain amount of Agaricus truncatus powder, heating in a water bath at 50° C., extracting twice, filtering the extract, and drying by rotation to obtain the crude product of Agaricus truncatus;

[0010] (3) Purification of Agaricus truncatus extract: dilute the Agaricus truncatus crude product with water and set the volume (the ratio of the Agaricus truncatus crude product to water is 15-20 g: 300 mL); add ethyl acetate to the fixed volume Agaricus truncatus crude product solution, extract three times, combine the ethyl acetate layer extracts, and distill under reduced pressure to remove the ethyl acetate to obtain the Agaricus truncatus extract.

[0011] Preferably, in step (2), the ethanol concentration is 95 v / v%, and the solid-liquid ratio of the Tricholoma australis powder to the ethanol added in each extraction is 1 g:10 mL.

[0012] Preferably, each ethanol extraction time in step (2) is 12 hours;

[0013] Preferably, in step (3), the volume ratio of the ethyl acetate added for each extraction to the constant volume crude solution of Agaricus oleifera is 1:1.

[0014] Furthermore, the inflammatory bowel disease is ulcerative colitis.

[0015] The subject of the drug for preventing and treating inflammatory bowel disease of the present invention is a human or an animal. In the present invention, "animal" means any animal that benefits from the improvement or reduction of the loss or other decline of the animal's age-related visual system, including humans, avian animals, bovine animals, canine animals, equine animals, feline animals, hicrine animals, lupine animals, murine animals, ovine animals, and porcine animals, and preferably domestic animals. Among them, domestic animals include dogs, cats, birds, rabbits, guinea pigs, ferrets, hamsters, mice, gerbils, recreational horses, cows, goats, sheep, donkeys, pigs, and more exotic species raised by humans.

[0016] Preferably, when the application object is a mouse, the effective dose of the Tricholoma australis extract is 200-400 mg / kg.

[0017] When the application object is human, the dosage can be converted into human dosage according to the relevant dosage standards in the pharmaceutical field.

[0018] When the single dose is large, it can be administered in multiple doses over multiple days.

[0019] Compared with the prior art, the present invention has the following advantages and beneficial effects:

[0020] The use of Agaricus tiliaceus extract in the preparation of drugs for the prevention and treatment of inflammatory bowel disease and other diseases has the following advantages: Agaricus tiliaceus is a species of fungus that grows in large quantities in pine forests in Northeast and North my country, and the raw materials are easy to collect and the cost is low; toxicology experiments have shown that Agaricus tiliaceus extract is non-toxic at lower concentrations and has high safety; the extraction and preparation process is simple.

[0021] The process is economical, low-cost, simple and easy to operate, has no environmental pressure, and is easy to realize industrial and large-scale production. The extraction is carried out using cheap and easily available Agrocybe truncatum, and the obtained active extract has significant anti-inflammatory bowel disease activity, and can be used to prepare drugs and auxiliary drugs for preventing or treating colitis. The daily edible fungus Agrocybe truncatum is fully utilized as a resource, reducing resource waste, providing active intermediates for the anti-inflammatory bowel disease pharmaceutical industry, and providing a new technical support for the research and development of anti-inflammatory bowel disease drugs, which has high application value and market prospects.

[0022] Experiments have shown that Tricholoma aconitifolia extract (hereinafter referred to as TTE) has a significant reducing effect on the disease activity index (DAI) of mice, can significantly alleviate symptoms such as colon shortening, colon damage, diarrhea and bloody stools, reduce tissue inflammatory cell infiltration, and has a significant protective effect on the colon; cell experiments have proved that TTE exerts an anti-inflammatory effect by significantly inhibiting LPS-induced NO production in RAW264.7 cells, significantly improving DSS-induced colitis, and effectively protecting the colon mucosa. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] In order to more clearly illustrate the technical solution of the present invention, the following briefly introduces the drawings required for use in the embodiments or the description of the prior art. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0024] Figure 1 It is a bar graph showing the effect of TTE on the viability of RAW264.7 cells;

[0025] Figure 2 It is a bar graph showing the effect of TTE on the NO level produced by LPS-induced RAW264.7 cells;

[0026] Figure 3 It is a curve diagram showing the inhibition rate of TTE on LPS-induced NO production in RAW264.7 cells;

[0027] Figure 4 The experimental flow chart of each group of mice;

[0028] Figure 5 The DAI score change index curve of each group of mice;

[0029] Figure 6 Figure 2 shows the colon morphology and length of mice in each group;

[0030] Figure 7 The figure is a statistical graph of the changes in colon length of mice in each group;

[0031] Figure 8 HE staining images of colon tissues of mice in each group. DETAILED DESCRIPTION

[0032] The applicant will now provide a clear and complete description of the technical solutions in the embodiments of the present invention in conjunction with the accompanying drawings in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0033] Example 1: A method for preparing a Tricholoma australis extract for preparing a drug for preventing and treating inflammatory bowel disease, the preparation method comprising the following steps:

[0034] (1) Pretreatment: Clean the Tricholomatreum to remove dust and granular impurities on the surface, dry and crush at 50° C. to obtain Tricholomatreum powder as an extraction raw material;

[0035] (2) Extracting the crude product of Agaricus truncatus: weighing 100 g of Agaricus truncatus powder, adding 1000 mL of 95% ethanol solution by volume each time, heating in a water bath at 50° C., extracting twice, each time for 12 h, filtering the extract, combining the two ethanol extracts, and drying them by rotary evaporation to obtain 18.32 g of the crude product of Agaricus truncatus;

[0036] (3) Purification of Trocholomatoderma extract: 18.32 g of the spin-dried crude product of Trocholomatoderma was diluted with pure water to 300 ml, and then an equal volume of ethyl acetate was added each time for extraction. The extraction was repeated three times, and the three ethyl acetate layer extracts were combined and distilled under reduced pressure to remove the ethyl acetate to obtain 4.82 g of a brown mobile paste extract with an extraction yield of 4.82%, which is the Trocholomatoderma extract.

[0037] Trocholomatoderma extract (hereinafter referred to as TTE), and the TTE used in the following examples is the TTE obtained in Example 1.

[0038] Example 2: Study on the anti-inflammatory activity of TTE in vitro in mouse model

[0039] Experimental methods:

[0040] 2.1 Cell recovery and culture

[0041] Take the mouse macrophage cell line RAW264.7 cells out of the liquid nitrogen tank, quickly put them into 37℃ warm water and shake them thoroughly to make them melt quickly. Then use a pipette to transfer the cell suspension in the cryopreservation tube to a 15mL centrifuge tube that has been sterilized by high pressure, and centrifuge at 1000rpm for 5min. Discard the supernatant, add 1mL of DMEM culture medium containing 10% fetal bovine serum, and gently blow to evenly form a cell suspension. Transfer the RAW264.7 cells to a cell culture bottle prepared with culture medium in advance, and place it in a constant temperature incubator at 37℃ 5% CO2 for subculture.

[0042] 2.2 Cell culture and passaging

[0043] Remove the cells from the incubator and observe that the cells cover 80% of the bottom area of ​​the culture medium before subculturing. Place the cell culture bottle on the clean bench, discard the old culture medium, add 2mL PBS (0.1M, pH7.4) to gently rinse the cells to remove the residual serum and cell metabolites in the bottle, and rinse repeatedly 2-3 times. Add an appropriate amount of fresh culture medium 4mL, use a disposable sterilized cell scraper to gently scrape the cells along the wall, and avoid scraping back and forth to avoid damaging the cells. Use a pipette to gently and repeatedly blow the cells apart. After blowing evenly, take 2mL of cell suspension to another culture bottle, add 2mL of fresh culture medium to the original cell culture bottle and the new culture bottle, and place them in a cell culture bottle at 37℃5% CO2 to continue culturing.

[0044] 2.3 Cell counting

[0045] Wipe the cell counting plate with 75% alcohol tissue in advance, draw the cell suspension and place it on the counting position of the cell counting plate, cover it with a cover glass, and make sure the counting position is evenly covered to avoid bubbles. Find the 4X4 grid under the microscope, observe and count, and use it for the inoculation density of the culture plate in subsequent experiments.

[0046] 2.4 CCK-8 assay to detect the effect of TTE on cell viability

[0047] Take RAW264.7 cells in logarithmic phase and count them. 5 The cell density of each well was inoculated on a 96-well plate, and 100 μL of cell suspension was added to each well and cultured in a constant temperature incubator. A blank control group, an LPS group, and a TTE experimental group with a final concentration of 0.08, 0.8, 1.6, 8, 16, 80, 160, and 800 μg / mL were set up. After the cells adhered to the wall, they were starved overnight with serum-free medium. The culture medium was discarded the next day. One hour after administration, LPS with a final concentration of 1 μg / mL was added to all groups except the blank group. After 24 hours, the supernatant was discarded, and 100 μL of the prepared CCK-8 solution was added to each well. After continuing to culture in the incubator for 1 and a half hours, the OD value was measured at a wavelength of 450 nm using an enzyme reader to calculate the relative cell survival rate. GraphPad Prism 5.0 software was used for graphing, and the data were expressed as the mean ± standard deviation of the relative cell survival rate. express.

[0048] 2.5 Griess method to determine the effect on NO production in cell supernatant

[0049] RAW264.7 cells were prepared into 1×10 5The cells were seeded at a concentration of 100 μg / mL and inoculated in a 96-well plate and cultured in a cell culture flask at 37°C and 5% CO2. A blank control group, an LPS group, and a TTE experimental group were set up. After cell starvation treatment, TTE was added to the TTE experimental group at concentrations of 0.08, 0.8, 1.6, 8, 16, 80, 160, and 800 μg / mL, respectively, and DMEM containing 0.1% DMSO was added to both the LPS and control groups. After 1 hour of culture, LPS with a final concentration of 1 μg / mL was added to all groups except the blank control group. After 24 hours of incubation, the 96-well plate was removed from the incubator, and 50 μL of the culture medium supernatant was aspirated into a new 96-well plate. According to the instructions for use of the Bio-Tech Nitric Oxide Detection Kit, 50 μL of Griess Reagent I was first added to each well, followed by 50 μL of Griess Reagent II. The reaction was protected from light for 10 minutes, and the OD value was measured at a wavelength of 540 nm. The NO content in the cell supernatant of each group was calculated using the nitrite standard curve. GraphPad Prism 5.0 software was used for plotting, and the data were expressed as the mean value ± standard deviation of the NO content. P < 0.05 was considered statistically significant.

[0050] Experimental results and analysis:

[0051] 2.6 Effect of TTE on cell viability

[0052] In this study, the CCK-8 method was used to determine the effect of different concentrations of TTE on RAW264.7 cells after 24 hours of action on cell viability. Figure 1 It can be seen that the purpose of the experiment is to screen the concentration of TTE that will not affect the normal growth and proliferation of cells. Therefore, the drug concentration when the relative cell survival rate is greater than 90% is the non-toxic concentration, thereby determining the safety of TTE on RAW264.7 cells. It is generally believed that the higher the non-toxic concentration, the safer the cell effect. The results show that TTE in the concentration range of 0-160μg / mL belongs to the non-toxic concentration, so it is believed that this concentration range is the safe concentration of TTE for RAW264.7 cells.

[0053] 2.7 Effect of TTE on NO in cell supernatant

[0054] Based on the determination of the safe concentration of TTE, this study used the Griess method to determine the NO content in the cell supernatant after TTE acted on LPS-induced RAW264.7 cells within the safe concentration range for 24 hours, and used the NO content as an indicator to explore its anti-inflammatory activity. Figure 2It can be seen that compared with the blank control group, the NO content in the cell supernatant of the LPS group was significantly increased (P<0.001), indicating that the inflammatory model was successfully established. The data showed that within the safe concentration range, 0.8-160μg / mL TTE had a significant effect on inhibiting the production of NO content. Figure 3 It can be seen that the IC of NO inhibition rate measured at the same time 50 =1.992μg / mL.

[0055] Example 3: Study on the anti-inflammatory activity of TTE in vivo in a mouse model

[0056] Experimental methods:

[0057] 3.1 Grouping and modeling

[0058] After 5 days of adaptive breeding, 30 mice were randomly divided into 5 groups, 1 normal group (NC), 2 model group (MC), 3 low-dose group (L-TTE), 4 medium-dose group (M-TTE) and 5 high-dose group (H-TTE), and ear tags were given to the mice respectively. The normal group (NC) was routinely fed with normal drinking water, and the other groups were free to drink 3% DSS solution for 7 consecutive days to induce ulcerative colitis. At the same time, the low-dose group (L-TTE), medium-dose group (M-TTE), and high-dose group (H-TTE) were gavaged with 40, 200, and 400 mg / kg of TTE every day, respectively, and the normal group (NC) and model group (MC) were gavaged with the same volume of 0.2% CMC-Na. The mice were killed on the eighth day.

[0059] 3.2 Evaluation of the Disease Activity Index (DAI) in Mice

[0060] The mice were weighed daily from day 0, and their status, feces characteristics, and blood in the stool were observed. The DAI score for fecal occult blood was calculated according to the method in Table 1.

[0061] Table 1 DAI scoring criteria

[0062]

[0063] 3.3 Specimen collection and processing

[0064] On the eighth day, the mice were killed by cervical dislocation after eyeball removal and blood collection. The blood was left at room temperature at 20℃ for 2h. After stratification, it was centrifuged at 1000rpm for 10min at 4℃, and the serum was transferred to a clean EP tube and stored at -80℃ for later use. The colon tissue was retained, and the anus to the end of the cecum was cut, the length was measured and photographed. Then, the feces in the colon was flushed with pre-cooled saline using a syringe, and the mesentery was cut and flattened, rolled into a Swiss roll shape, and routine paraffin-embedded sections were performed, HE staining, and the degree of colon pathological changes was observed under a microscope.

[0065] Experimental results and analysis

[0066] 3.4 Changes in Disease Activity Index (DAI)

[0067] Figure 4 The figure is the flow chart of animal experiment. DAI score was calculated based on the daily detected weight, stool characteristics and blood in stool of mice. The results showed that compared with the normal group (NC), the DAI score of the model group (MC) increased. Compared with the model group (MC), the DAI scores of the drug-treated groups decreased to varying degrees, among which the high-dose group (H-TTE) showed the most significant downward trend, as shown in Figure 2. Figure 5 It is knowable.

[0068] 3.5 Colon morphology and length measurement

[0069] After administration of DSS, the colon of mice was significantly shortened, and dark red feces appeared in the colon and cecum. Figure 6 After low-dose TTE intervention, no significant changes were found; after medium-dose TTE intervention, it was found that the colon length was restored; the colon length of mice in the high-dose group (H-TTE) increased significantly, as shown by Figure 7 The results are expressed as Mean±SD, ***P<0.001.

[0070] 3.6 Colon pathological histological observation

[0071] The results of HE staining of colon tissue pathological sections showed that the colon of the blank control group was intact, while the mucosal layer of the model group was largely lost, the structure of the muscular layer and mucosal layer was disordered, the boundary was unclear, and inflammatory cells were infiltrated. The colon tissue of the low-dose group (L-TTE) lost a lot of mucosal layer but the muscular layer structure was intact: the colon tissue of the medium-dose group (M-TTE) and the high-dose group (H-TTE) had obvious recovery compared with the model group (MC), Figure 8 It is knowable.

[0072] In summary, TTE can significantly inhibit LPS-induced NO production in RAW264.7 cells, and its IC 50 The concentration of TTE in ulcerative colitis was 1.992 μg / mL. In the ulcerative colitis experiment, TTE can significantly improve DSS-induced colitis. The present invention provides an experimental basis for the development of drugs for preventing and treating inflammatory bowel disease and ulcerative colitis.

[0073] The above description is only a specific implementation of the present invention, but the protection scope of the present invention is not limited thereto. Any changes or substitutions that can be understood by anyone familiar with the technology within the technical scope disclosed by the present invention should be included in the scope of the present invention.

Claims

1. A use of a Tricholoma australis extract in the preparation of a drug for preventing and treating inflammatory bowel disease, characterized in that: The Tricholoma australis extract is the only active ingredient, and the preparation method of the Tricholoma australis extract comprises the following steps: (1) Pretreatment: Clean the brown gray mushroom, dry it at low temperature and then crush it to obtain brown gray mushroom powder as the extraction raw material; (2) Extracting the crude product of Agaricus truncatus: adding ethanol to Agaricus truncatus powder, heating in a water bath at 50° C., extracting twice, filtering the extracts, and drying the extracts obtained twice to obtain the crude product of Agaricus truncatus; (3) Purifying the Agaricus truncatus extract: diluting the Agaricus truncatus crude product with water and then fixing the volume to obtain an Agaricus truncatus crude product solution; then adding ethyl acetate, extracting three times, combining the three ethyl acetate layer extracts, and removing the ethyl acetate by vacuum distillation to obtain the Agaricus truncatus extract; The ethanol concentration in step (2) is 95%.

2. The use of a Tricholoma australis extract according to claim 1 in preparing a drug for preventing and treating inflammatory bowel disease, characterized in that: In step (2), the solid-liquid ratio of the Tricholoma agrocybe powder to the ethanol added in each extraction is 1 g: 10 mL.

3. The use of a Tricholoma australis extract according to claim 1 in preparing a drug for preventing and treating inflammatory bowel disease, characterized in that: Each ethanol extraction in step (2) takes 12 hours.

4. The use of a Tricholoma australis extract according to claim 1 in preparing a drug for preventing and treating inflammatory bowel disease, characterized in that: The volume ratio of the ethyl acetate added each time in step (3) to the crude solution of Agaricus oleifera after volume adjustment is 1:

1.

5. The use of a Tricholoma australis extract according to claim 1 in preparing a drug for preventing and treating inflammatory bowel disease, characterized in that: The inflammatory bowel disease is ulcerative colitis.